Clinical Trials - April 1, 2015
Liver Disease Drug Trial Starts
Biotie Therapies Corp. of Finland has started patient enrollment into the Phase 2a clinical study evaluating BTT1023, Biotie’s fully human monoclonal antibody targeting Vascular Adhesion Protein-1, in primary sclerosing cholangitis (PSC). PSC is a progressive disease characterized by bile duct inflammation and fibrosis, and accompanying hepatic fibrosis, that frequently results in the need for a […]
